Francisella novicida Cas9 (FnCas9) has low cellular editing ability which limits its therapeutic utilities. Here, the authors rationally engineer the protein to develop enhanced FnCas9 (enFnCas9) variants with high on-target editing efficiency, high precision, broadened target range, and flexible base editing outcomes.
- Sundaram Acharya
- Asgar Hussain Ansari
- Debojyoti Chakraborty